Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M., Savoie, M., Spellman, S. R., Confer, D. L., Chell, J., Brown, M., Medeiros, B. C., Sekeres, M. A., Lin, T. L., Uy, G. L., Powell, B. L., Kolitz, J. E., Larson, R. A., Stone, R. M., Claxton, D. F., Essell, J., Luger, S., Mohan, S. R., Moseley, A., Erba, H. P., Appelbaum, F. R. AMER SOC HEMATOLOGY. 2016
View details for Web of Science ID 000394446807012